02512nas a2200265   4500000000100000008004100001653001200042653002400054653002000078653002500098653001700123100001500140700002000155700001700175700001500192700001500207700001300222700001600235245009800251856008200349300001000431490000700441520178400448022001402232       2019                            d10aleprosy10aClinicopathological10ahistopathologic10aMycobacterium leprae10aSaudi Arabia1 aAlakloby O1 aAlabdulkareem A1 aM. Aljabre S1 aRandhawa M1 aAlakloby E1 aAljabr A1 aAlmutairi A00aClinicopathological correlation of leprosy and response to treatment in Eastern Saudi Arabia.  uhttp://www.jddsjournal.org/temp/JDermatolDermatolSurg23130-3808858_103448.pdf  a30-340 v233 a<p><strong>Background:</strong> Leprosy is a chronic, progressing, and disabling disease caused by <em>Mycobacterium leprae</em>, predominantly affecting the skin and peripheral nerves. <strong>Aim:</strong> The aim is to study clinicopathological correlation and response to treatment in leprosy patients attending King Fahd Hospital of University (KFHU), Al-Khobar, Eastern Saudi Arabia. <strong>Methodology:</strong> Records of all cases attending Dermatology Department of KFHU from 1985 to 2005 and labeled clinically as leprosy were retrieved. Their clinical data and histopathologic slides were reviewed. Many of the expatriates left Saudi Arabia after diagnosis. The remaining ones and Saudi nationals received the WHO standard treatment for 12 months and 18 months for paucibacillary and multibacillary leprosy, respectively. <strong>Results:</strong> Among 87 cases, there was a good clinicopathological correlation; the most common forms of leprosy clinically and histologically were of borderline leprosy (BB), 31 (35.63%) and 34 (39.08%), followed by tuberculoid type (TT), 22 (25.29%) and 27 (31.03%); lepromatous leprosy, 18 (20.69%) and 17 (19.54%); erythema nodosum leprosum (ENL), 6 (6.9%) and 5 (5.75%); indeterminate leprosy, 4 (4.6%) and 4 (4.6%); and nonspecific, 6 (6.9%). Thirty-two patients received the WHO standard treatment for paucibacillary and multibacillary leprosy, respectively; all cases showed complete clinical improvement with 24-month follow-up, except for two paucibacillary cases who developed ENL and lost follow-up after 16 months. <strong>Conclusions:</strong> There was a good clinicopathological correlation. The response to treatment was good in those who continued treatment and better in TT than lepromatous type of leprosy.</p>
  a2352-2410